tetano
Editor, Senior Moderator
J Autoimmun
. 2022 Oct 4;133:102925.
doi: 10.1016/j.jaut.2022.102925. Online ahead of print.
Risk for uveitis relapse after COVID-19 vaccination
Zhenyu Zhong[SUP] 1 [/SUP], Qiuying Wu[SUP] 1 [/SUP], Yuxian Lai[SUP] 1 [/SUP], Lingyu Dai[SUP] 1 [/SUP], Yu Gao[SUP] 1 [/SUP], Weiting Liao[SUP] 1 [/SUP], Xiaojie Feng[SUP] 1 [/SUP], Peizeng Yang[SUP] 2 [/SUP]
Affiliations
Abstract
Objectives: Several studies suggested that coronavirus disease 2019 (COVID-19) vaccination may lead to uveitis, a vision-threatening condition often associated with a variety of autoimmune or autoinflammatory diseases. This study aims to explore factors that influence the risk of uveitis relapse after COVID-19 vaccination to guide the prevention of disease.
Methods: Uveitis relapse was evidenced by worsening activity of intraocular inflammation (e.g. anterior chamber cells, vitreous haze) as defined by the Standardization of Uveitis Nomenclature Working Group. Time to uveitis relapse since the administration of each dose of COVID-19 vaccine was compared across participants with modifiable variables.
Results: The primary analysis included 438 non-COVID-19 participants with 857 doses of COVID-19 vaccine administered in total. The median age was 41 years (interquartile range, 30 to 51), and 57.3% were female. A total of 39 episodes of uveitis relapse events occurred in 34 patients after the receipt of a dose of COVID-19 vaccine within 30 days. The median time to relapse after vaccination was 5 days (interquartile range, 1 to 14). Concomitant use of systemic glucocorticoids at the time of vaccination was independently associated with a decrease in risk of relapse after vaccination (HR, 0.23 [95% CI, 0.07-0.74]; P value = 0.014). There was a trend in attenuating the risk of relapse with increasing prednisone dose from none to less than 20 mg per day and then to 20 mg per day or greater (P value for trend = 0.029).
Conclusions: Concomitant treatment with systemic glucocorticoids for uveitis at the time of COVID-19 vaccination was associated with a dose-dependent lower risk of uveitis relapse after vaccination.
Keywords: COVID-19; Uveitis relapse; Vaccination.
. 2022 Oct 4;133:102925.
doi: 10.1016/j.jaut.2022.102925. Online ahead of print.
Risk for uveitis relapse after COVID-19 vaccination
Zhenyu Zhong[SUP] 1 [/SUP], Qiuying Wu[SUP] 1 [/SUP], Yuxian Lai[SUP] 1 [/SUP], Lingyu Dai[SUP] 1 [/SUP], Yu Gao[SUP] 1 [/SUP], Weiting Liao[SUP] 1 [/SUP], Xiaojie Feng[SUP] 1 [/SUP], Peizeng Yang[SUP] 2 [/SUP]
Affiliations
- PMID: 36209692
- DOI: 10.1016/j.jaut.2022.102925
Abstract
Objectives: Several studies suggested that coronavirus disease 2019 (COVID-19) vaccination may lead to uveitis, a vision-threatening condition often associated with a variety of autoimmune or autoinflammatory diseases. This study aims to explore factors that influence the risk of uveitis relapse after COVID-19 vaccination to guide the prevention of disease.
Methods: Uveitis relapse was evidenced by worsening activity of intraocular inflammation (e.g. anterior chamber cells, vitreous haze) as defined by the Standardization of Uveitis Nomenclature Working Group. Time to uveitis relapse since the administration of each dose of COVID-19 vaccine was compared across participants with modifiable variables.
Results: The primary analysis included 438 non-COVID-19 participants with 857 doses of COVID-19 vaccine administered in total. The median age was 41 years (interquartile range, 30 to 51), and 57.3% were female. A total of 39 episodes of uveitis relapse events occurred in 34 patients after the receipt of a dose of COVID-19 vaccine within 30 days. The median time to relapse after vaccination was 5 days (interquartile range, 1 to 14). Concomitant use of systemic glucocorticoids at the time of vaccination was independently associated with a decrease in risk of relapse after vaccination (HR, 0.23 [95% CI, 0.07-0.74]; P value = 0.014). There was a trend in attenuating the risk of relapse with increasing prednisone dose from none to less than 20 mg per day and then to 20 mg per day or greater (P value for trend = 0.029).
Conclusions: Concomitant treatment with systemic glucocorticoids for uveitis at the time of COVID-19 vaccination was associated with a dose-dependent lower risk of uveitis relapse after vaccination.
Keywords: COVID-19; Uveitis relapse; Vaccination.